
## Arijit Sil

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4420503/publications.pdf Version: 2024-02-01



Δριμτ ςμ

#	Article	IF	CITATIONS
1	Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. Vaccine, 2020, 38, 4476-4483.	3.8	14
2	Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine, 2020, 27, 100540.	7.1	14
3	Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants. Human Vaccines and Immunotherapeutics, 2016, 12, 946-954.	3.3	10
4	Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants. Vaccine, 2017, 35, 2999-3006.	3.8	9
5	A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report. BMC Pediatrics, 2020, 20, 480.	1.7	7
6	One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine. International Journal of Infectious Diseases, 2020, 93, 102-107.	3.3	7
7	Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose. Npj Vaccines, 2022, 7, 12.	6.0	2
8	A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age. The Lancet Regional Health - Western Pacific, 2022, 24, 100484.	2.9	1